reaching every heart’s
potential

Patient well-being is at the core of everything we do. 

And it’s where our unwavering focus will always
be. Because like you, we’re relentlessly
dedicated to restoring healthy hearts that are
filled with possibilities. And ready to make a 
lifetime of cherished memories.

 

Our Solutions     Abbott Structural Heart

Explore the Abbott Portfolio of
Structural Heart Solutions

MitraClip
LEADING EXPERIENCE.
LASTING CONFIDENCE.

Abbott pioneered the breakthrough MitraClip therapy, which provides unmatched TMVr efficacy.1-4

 

Learn more

Amplatzer PFO Occluder
THE LEADING PFO
CLOSURE DEVICE5

Amplatzer PFO Occluder created the category of PFO occlusion, sustained leadership over decades of use, and was the first device supported by positive PFO trial results.

 

Learn more

Portico
THINK YOU KNOW PORTICO?
THINK AGAIN.

Portico is the first fully resheathable, repositionable, and retrievable aortic valve used for transcatheter aortic valve implantation (TAVI).

 

Learn more

Every Heart has
a Story

The testimonials relate to accounts of individuals’ responses to treatments. The patients’ accounts are genuine, typical and documented. However, it does not provide any indication, guide, warranty, or guarantee as to the response other persons may have to the treatment. Responses to the treatment discussed can and do vary and are specific to the individual patient.

Derek: “It’s Life-Changing” to Receive an LAA Occluder

Derek, who had atrial fibrillation and whose left atrial appendage (LAA) contributed to a stroke, was treated with anticoagulants—but they resulted in a cerebral hemorrhage. David Hildick-Smith, MD, noted that Amplatzer LAA occlusion “reduces the risk of stroke very substantially, but it also offers patients a peace of mind [when they otherwise are] unprotected from the risk of stroke.”

Alan: Finally “Getting the Care” He Needed with Amplatzer PFO Occluder

“It’s scary,” said Alan, who had had a stroke due to a patent foramen ovale, and who didn’t know if and when he might have a recurrent stroke. After Amplatzer PFO closure “He’s like a new man,” his wife, Emma, remarked about Alan, who’s back to walking 12 miles a day as a mail carrier. “And I owe everyone a massive thank you,” Alan said.

Jozef: “Finding Just the Right Device” Helped Turn His Life Around

Over time Jozef’s ventricular septal defect (VSD) precipitated endocarditis, which in turn led to heart failure and kidney failure. After receiving the Amplatzer VSD Occluder Jozef, amazed at his symptom improvement and ability to walk long distances again, said “I feel joy deep inside me—inside my heart.”

Gareth: Getting “A Second Life” with Transcatheter Aortic Valve Implantation (TAVI)

“It was so successful in terms of symptom relief, and his recovery was astoundingly quick,” explained Dave Smith, MD, interventional cardiologist who treated Gareth with the Portico valve. “My life is back, and I can do everything now,” said Gareth.

Alessandro: “I Was at the End of My Life” Before Receiving MitraClip

“I couldn’t walk anymore, I couldn’t climb stairs, I couldn’t do anything,” said Alessandro. After receiving MitraClip which eliminated his mitral regurgitation, “I started to feel well, my breathing was good again, and I could return to cutting grass with a scythe—really my life had begun again.”

AP2947148-WBO Rev. A

References
  1. Feldman T, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol. 2015;66:2844–54) © 2015 by the American College of Cardiology Foundation.
  2. Kar S, Whitlow P, Pedersen W, et al. Effectiveness of transcatheter reduction of significant mitral regurgitation in high surgical risk patients with MitraClip: final 5-year results of the EVEREST II High Risk Registry presented at ACC 2014; March 29, 2014; Washington, DC.
  3. Sorajja P, et al. Initial experience with commercial transcatheter mitral valve repair in the United States. J Am Coll Cardiol. 2016;67(10):1129-1140.
  4. Ailawadi G. Updated MitraClip outcomes from the STS TVT Registry. On behalf of the TVT Registry. May 5, 2016.
  5. Data on file at Abbott.

This site uses cookies to improve your experience.

To find out more please read our Privacy and Cookies policy.

Ok

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.